Top Story Today
A Two-Year Death Sentence Just Got Interrupted for the First Time
Ionis and Otsuka's ulefnersen just delivered the strongest survival data ever seen in FUS-ALS, a genetic form of Lou Gehrig's disease that typically kills patients within two years, often before age 40. The Phase 3 FUSION trial hit its primary endpoint with a p-value of 0.0005, showing the drug significantly prolonged survival and slowed disease progression. Blood biomarkers of nerve damage dropped sharply versus placebo, and the safety profile looked clean. Otsuka plans to pursue expedited FDA pathways for a disease that has zero targeted treatments.
Why it matters: This validates the precision medicine playbook for ALS: target a specific genetic mutation, design a molecule to neutralize it, and prove it keeps patients alive longer. Each genetic subtype cracked open brings the field one step closer to treating neurodegeneration like the molecular disease it is.
Read more →Clinical Wins (and One Awkward Celebration)
Celldex Aced Both Finals and Still Got Sent to the Principal's Office
Barzolvolimab swept both Phase 3 trials for chronic hives, with complete response rates above 42% (versus roughly 10% on placebo) and p-values below 0.00001. Wall Street responded by dumping the stock 11.6%. The culprit: two anaphylaxis cases and a neutropenia signal in 9-12% of patients. Most analysts called the selloff an overreaction.
Read more →The Disease Nobody Could Treat Just Got Its First Real Drug
Amgen's dazodalibep hit its primary endpoint in a 621-patient Phase 3 trial for Sjogren's disease, a condition with zero FDA-approved targeted therapies. Patients improved as early as week four, with benefits holding through 48 weeks. The drug, inherited through Amgen's $27.8 billion Horizon acquisition, blocks immune cell crosstalk without the blood-clot risk that killed earlier attempts at this mechanism.
Read more →Merck's PAH Drug Adds a 76% Risk Reduction to Its Resume
WINREVAIR's FDA label now includes Phase 3 HYPERION data showing a 76% reduction in clinical worsening for recently diagnosed PAH patients. Only 10.6% of treated patients got worse, versus 36.9% on placebo. The drug already pulled in $1.4 billion in its first full year, and analysts see peak sales north of $3 billion.
Read more →Setbacks and Stumbles
Novartis's $12 Billion Platform Bet Takes a Hit
Novartis's antibody-oligonucleotide conjugate platform, acquired from Avidity Biosciences for $12 billion, has stumbled in clinical trials. The lead program del-desiran missed its Phase 3 endpoint in myotonic dystrophy. Analysts are questioning the due diligence behind the deal as Novartis faces its biggest patent cliff in history.
Read more →Sarepta Gets a Black Box, Cuts 500 Jobs, and Trades at $20
Sarepta added the FDA's most serious safety warning to its Duchenne gene therapy Elevidys (for fatal liver injury) while cutting 36% of its workforce. Elevidys product revenue has cratered roughly 74% from its Q1 2025 peak. Analyst price targets range from $5 to $38, which tells you exactly how much consensus exists: none.
Read more →Immunovant's Lupus Key Didn't Turn
Immunovant killed its cutaneous lupus program after IMVT-1402 failed to beat placebo in a 57-patient Phase 2 trial. The result reinforces an emerging pattern: FcRn inhibitors work beautifully when rogue antibodies are the main villain but struggle in diseases with messier immunology. The remaining pipeline (Graves', myasthenia gravis, CIDP) looks better positioned.
Read more →Deals and Policy Moves
Novartis Writes a $900M Check for a Drug Nobody Can Describe
Novartis licensed a preclinical radioligand therapy from China's Boomray Pharmaceuticals for up to $900 million. The target, cancer type, and isotope remain undisclosed. With BMS, Lilly, and AstraZeneca all spending billions on radiopharmaceutical acquisitions, Novartis is paying the early-bird premium to stay ahead in an arms race it helped create.
Read more →HHS Just Told Lab Mice to Update Their Resumes
HHS announced 20-plus federal initiatives and $88 million in NIH funding to replace animal testing with AI, organoids, and organ-on-a-chip systems. The FDA is also scrubbing animal-specific language from its regulations. Roughly 90-96% of drugs fail between lab and pharmacy; the government is betting that better preclinical models can change those odds.
Read more →